- Home
- Publications
- Publication Search
- Publication Details
Title
Targeting the PD-1/ PD-L1 interaction in nasopharyngeal carcinoma
Authors
Keywords
Nasopharyngeal carcinoma, Programmed cell death receptor ligand-1, Immune-checkpoint inhibitor
Journal
ORAL ONCOLOGY
Volume 113, Issue -, Pages 105127
Publisher
Elsevier BV
Online
2021-01-15
DOI
10.1016/j.oraloncology.2020.105127
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal cancer
- (2020) Jin Zhao et al. CANCER LETTERS
- The efficacy and safety of PD-1/PD-L1 inhibitors in patients with recurrent or metastatic nasopharyngeal carcinoma: A systematic review and meta-analysis
- (2020) Bi-Cheng Wang et al. ORAL ONCOLOGY
- Preliminary results with tislelizumab, an investigational anti-PD-1 antibody, in Chinese patients with nasopharyngeal cancer (NPC).
- (2019) Siyang Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Recombinant humanized anti-PD-1 monoclonal antibody (JS001) in patients with refractory/metastatic nasopharyngeal carcinoma: Interim results of an open-label phase II clinical study.
- (2019) Fenghua Wang et al. JOURNAL OF CLINICAL ONCOLOGY
- Tabelecleucel in combination with pembrolizumab (Pembro) in platinum-pretreated, recurrent/metastatic Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (EBV+NPC).
- (2019) Lillian L. Siu et al. JOURNAL OF CLINICAL ONCOLOGY
- A Phase I/II Open‐Label Study of Nivolumab in Previously Treated Advanced or Recurrent Nasopharyngeal Carcinoma and Other Solid Tumors
- (2019) Yuxiang Ma et al. ONCOLOGIST
- Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
- (2019) Yuan Zhang et al. NEW ENGLAND JOURNAL OF MEDICINE
- Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
- (2019) Steve Lu et al. JAMA Oncology
- Management of locally recurrent nasopharyngeal carcinoma
- (2019) Anne W.M. Lee et al. CANCER TREATMENT REVIEWS
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- Translational genomics of nasopharyngeal cancer
- (2019) Chi Man Tsang et al. SEMINARS IN CANCER BIOLOGY
- Interferon β and Anti-PD-1/PD-L1 Checkpoint Blockade Cooperate in NK Cell-Mediated Killing of Nasopharyngeal Carcinoma Cells
- (2019) Anna Makowska et al. Translational Oncology
- Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
- (2019) Barbara Burtness et al. LANCET
- Development and validation of an immune checkpoint-based signature to predict prognosis in nasopharyngeal carcinoma using computational pathology analysis
- (2019) Ya-Qin Wang et al. Journal for ImmunoTherapy of Cancer
- Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
- (2019) Jianchun Duan et al. JAMA Oncology
- Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results
- (2018) Jiyi Hu et al. CANCER
- Efficacy, Safety, and Pharmacokinetics of Axitinib in Nasopharyngeal Carcinoma: A Preclinical and Phase II Correlative Study
- (2018) Edwin P. Hui et al. CLINICAL CANCER RESEARCH
- Detailed analysis of inflammatory cell infiltration and the prognostic impact on nasopharyngeal carcinoma
- (2018) Juan Lu et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742)
- (2018) Brigette B.Y. Ma et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of Plasma Epstein-Barr Virus DNA in Nasopharyngeal Cancer After Chemoradiation to Identify High-Risk Patients for Adjuvant Chemotherapy: A Randomized Controlled Trial
- (2018) Anthony T.C. Chan et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study)
- (2018) K.H. Au et al. ORAL ONCOLOGY
- Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
- (2018) Aaron M. Goodman et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
- (2018) Wenfeng Fang et al. LANCET ONCOLOGY
- Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial
- (2017) Su-Mei Cao et al. EUROPEAN JOURNAL OF CANCER
- Phase 2 Multicenter Trial Evaluating the Role of Induction TPF Followed by Weekly Docetaxel and Cetuximab in Combination With IMRT for Locally Recurrent Nasopharyngeal Carcinoma
- (2017) W.T. Ng et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1–Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study
- (2017) Chiun Hsu et al. JOURNAL OF CLINICAL ONCOLOGY
- What Is the Best Treatment of Locally Advanced Nasopharyngeal Carcinoma? An Individual Patient Data Network Meta-Analysis
- (2017) Laureen Ribassin-Majed et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic role of tumour-associated macrophages and regulatory T cells in EBV-positive and EBV-negative nasopharyngeal carcinoma
- (2017) Marc L Ooft et al. JOURNAL OF CLINICAL PATHOLOGY
- Characterization of PD-L1 expression and immune cell infiltration in nasopharyngeal cancer
- (2017) Oscar Siu Hong Chan et al. ORAL ONCOLOGY
- Prognostic role of tumor infiltrating lymphocytes in EBV positive and EBV negative nasopharyngeal carcinoma
- (2017) Marc L. Ooft et al. ORAL ONCOLOGY
- Exome and genome sequencing of nasopharynx cancer identifies NF-κB pathway activating mutations
- (2017) Yvonne Y Li et al. Nature Communications
- Tumor cells PD-L1 expression as a favorable prognosis factor in nasopharyngeal carcinoma patients with pre-existing intratumor-infiltrating lymphocytes
- (2017) Qian Zhu et al. OncoImmunology
- The immunologic advantage of recurrent nasopharyngeal carcinoma from the viewpoint of Galectin-9/Tim-3-related changes in the tumour microenvironment
- (2017) Tseng-Cheng Chen et al. Scientific Reports
- Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial
- (2016) Li Zhang et al. LANCET
- Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial
- (2016) Ying Sun et al. LANCET ONCOLOGY
- Management of Nasopharyngeal Carcinoma: Current Practice and Future Perspective
- (2015) Anne W.M. Lee et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis
- (2015) Pierre Blanchard et al. LANCET ONCOLOGY
- EBV-driven LMP1 and IFN-γ up-regulate PD-L1 in nasopharyngeal carcinoma: Implications for oncotargeted therapy
- (2015) Wenfeng Fang et al. Oncotarget
- Local failure patterns for patients with nasopharyngeal carcinoma after intensity-modulated radiotherapy
- (2014) Jia-xin Li et al. Radiation Oncology
- PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
- (2013) B. J. Chen et al. CLINICAL CANCER RESEARCH
- Challenges in the modification of the M1 stage of the TNM staging system for nasopharyngeal carcinoma: A study of 1027 cases and review of the literature
- (2012) CHANG-CHUAN PAN et al. Experimental and Therapeutic Medicine
- Hemorrhagic complications in a phase II study of sunitinib in patients of nasopharyngeal carcinoma who has previously received high-dose radiation
- (2011) E. P. Hui et al. ANNALS OF ONCOLOGY
- Capecitabine Monotherapy for Recurrent and Metastatic Nasopharyngeal Cancer
- (2008) D. Chua et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Randomized Phase II Trial of Concurrent Cisplatin-Radiotherapy With or Without Neoadjuvant Docetaxel and Cisplatin in Advanced Nasopharyngeal Carcinoma
- (2008) Edwin P. Hui et al. JOURNAL OF CLINICAL ONCOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started